Sarcoma | Zendy

Maki Robert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sarcoma

Author(s) -

Maki Robert

Publication year - 2001

Publication title -

the oncologist

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.176

H-Index - 164

eISSN - 1549-490X

pISSN - 1083-7159

DOI - 10.1634/theoncologist.6-4-333

Subject(s) - medicine , imatinib mesylate , imatinib , sarcoma , chronic myelogenous leukemia , tyrosine kinase inhibitor , soft tissue sarcoma , trabectedin , tyrosine kinase , rhabdomyosarcoma , oncology , ifosfamide , cancer research , leukemia , chemotherapy , pathology , cancer , etoposide , receptor , myeloid leukemia

ASCO 2001 was a banner year for innovative systemic therapy for sarcomas. Imatinib mesylate (STI571, Gleevec tm ) shows clear activity not only in chronic myelogenous leukemia, for which the drug received Food and Drug Administration approval, but also in gastrointestinal stromal tumors as well, by virtue of imatinib mesylate binding to the abl , kit , and platelet‐derived growthfactor receptor tyrosine kinases. Ecteinascidin‐743 (ET‐743) demonstrates activity against a fraction of other soft‐tissue sarcomas. Gemcitabine‐based regimens show at least some activity against a subset of soft‐tissue sarcomas. Given the lack of new agents for sarcoma therapy since the development of ifosfamide, these studies give hope that the term “effective systemic therapy for sarcoma” might become a reality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research